Ironwood Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:IRWD)

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) saw unusually large options trading activity on Monday. Traders acquired 3,553 call options on the company. This is an increase of approximately 1,479% compared to the average volume of 225 call options.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. OVERSEA CHINESE BANKING Corp Ltd acquired a new stake in Ironwood Pharmaceuticals during the 2nd quarter valued at $25,000. R Squared Ltd grew its holdings in Ironwood Pharmaceuticals by 286.5% during the 2nd quarter. R Squared Ltd now owns 38,765 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 28,735 shares in the last quarter. Focus Partners Advisor Solutions LLC grew its holdings in Ironwood Pharmaceuticals by 284.6% during the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 29,409 shares in the last quarter. Captrust Financial Advisors acquired a new stake in Ironwood Pharmaceuticals during the 2nd quarter valued at $32,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in Ironwood Pharmaceuticals during the 2nd quarter valued at $36,000.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on IRWD. Wall Street Zen upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ironwood Pharmaceuticals in a report on Wednesday, October 8th. Finally, Zacks Research raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Ironwood Pharmaceuticals has an average rating of “Hold” and an average target price of $4.94.

Ironwood Pharmaceuticals Trading Down 3.1%

Shares of IRWD stock opened at $1.86 on Tuesday. The company’s fifty day simple moving average is $1.43 and its 200-day simple moving average is $1.01. Ironwood Pharmaceuticals has a 52 week low of $0.53 and a 52 week high of $5.13. The company has a market cap of $302.13 million, a PE ratio of -37.19 and a beta of 0.30.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Thursday, August 7th. The biotechnology company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. The business had revenue of $85.24 million for the quarter, compared to the consensus estimate of $62.02 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts expect that Ironwood Pharmaceuticals will post 0.1 EPS for the current fiscal year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.